REGENXBIO Inc.

RGNX

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Redmile Group

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Redmile GroupNEWFeb 17, 2026

Shares: 4,368,804Value: $62.9M

# RGNX Signal Note Redmile's $62.9M initiation in RGNX suggests conviction in the company's NAV gene therapy pipeline, likely driven by near-term catalysts in hemophilia B (valoctocogene roxaparvovec) commercial execution or upcoming data readouts in other rare genetic programs. Jeremy Green's healthcare crossover positioning typically indicates a deep-dive thesis on clinical/commercial inflection points rather than speculative risk-taking. The timing warrants monitoring of Q4 2024 hemophilia B uptake metrics and any upcoming Phase 2/3 readouts in the current pipeline.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ATRA1 fund IMNM1 fund KRYS1 fund ADCT1 fund KLRS1 fund CLDX1 fund CBLL1 fund NGNE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: